

ABUNDANT PRODUCE LIMITED

ABN 46 606 255 887

ASX APPENDIX 4D

RESULTS FOR ANNOUNCEMENT TO THE MARKET FOR THE SIX MONTHS ENDED 31 DECEMBER 2019

The following information should be read in conjunction with both the Financial Report for the year ended 30 June 2019 and the Interim Report for the half year ended 31 December 2019 and the attached auditors' review report.

This Appendix 4D is prepared in accordance with ASX Listing Rule 4.2A.3.

Reporting Period: Half-year from 1 July 2019 to 31 December 2019.

Previous corresponding period: Half-year from 1 July 2018 to 31 December 2018.

Financial Results

Revenue from ordinary activities for the period:	Down 41% by \$383,335 to \$555,751
Loss from ordinary activities after tax for the period attributable to members:	Up 43% by \$425,321 to (\$1,421,575)
Net loss after tax for the period attributable to members:	Up 43% by \$425,321 to (\$1,421,575)

The Company does not propose to pay dividends in the current period.

The Group incurred an after-tax loss attributed to members of \$1,421,575 for the six months to 31 December 2019 (2018: \$996,254 loss).

Significant Events since Balance Sheet Date

In February 2020, the Directors concluded that the costs and compliance obligations associated with maintaining an Australian Securities Exchange (ASX) listing were no longer justified given a share price considered to be significantly lower than the value of the business, and trading volumes insufficient to provide shareholders with meaningful liquidity. The Board further concluded that Abundant's ASX listing no longer offers a cost-effective mechanism for raising the capital required to grow Abundant Natural Health's business worldwide.

The Directors believe the long-term interests of shareholders are best served by delisting, accessing private equity and government assistance, and growing the ANH therapeutic products business until such time as sales revenue (and capital requirements) justify a new healthcare products listing. Accordingly, on 12 February 2020 ABT submitted a formal application for the removal of the company's ordinary shares from the official list of the ASX. The Board expects that the shares will be delisted in March 2020 (subject to formal approval by ASX).

Abundant is committed to growing revenues sufficiently to allow the payment of dividends and, in time, returning to the ASX, offering shareholders the benefit of a liquidity event.

Except for the above, no other matters or circumstances have arisen since the 31 December 2019 which significantly affected or could significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

Net Tangible Assets

	As at 31/12/2019	As at 30/06/2019
Net tangible assets per ordinary share	2.70 cents	3.73 cents

The accounts presented include an auditors' review report.